Abstract
Since the first description of self-reactive antibodies in systemic autoimmune rheumatic diseases, many autoantigens have been identified as useful diagnostic biomarkers in clinical immunology. Among the autoantigens, double-stranded desoxoribonucleic acid (dsDNA), the Smith antigen (Sm), topoisomerase-I (topo-I), proliferating cell nuclear antigen (PCNA), and others were described as hallmark targets of systemic autoimmune diseases. The detection of the corresponding autoantibodies can be performed with a variety of immunoassays based on native antigens, recombinant proteins or synthetic peptides. As discussed in this review, synthetic peptides often represent highly accurate antigenic ligands for autoantibody assays that can be easily produced in high quality and quantity and with remarkable reproducibility. Furthermore, the use of peptides that focus on abrogation or neutralization of pathogenic autoantibodies provides a possible new therapeutic approach to the management of autoimmune disorders. There is an increasing number of interesting examples for the application of synthetic peptides in diagnostic approaches. Todays sophisticated epitope mapping methods will potentate the identification of further peptides that can be possibly used as specific targets in diagnostic and therapeutic approaches to improve the patients treatment. This may lead to a new scientific research area with high impact on the development of diagnostic and therapeutic products, to the area of peptide engineering and “theranostics”.
Keywords: Peptide, autoantibody, SLE, dsDNA, Systemic rheumatic disease
Current Medicinal Chemistry
Title: Synthetic Peptides: The Future of Patient Management in Systemic Rheumatic Diseases?
Volume: 14 Issue: 26
Author(s): Kai Kessenbrock, Reinout Raijmakers, Marvin J. Fritzler and Michael Mahler
Affiliation:
Keywords: Peptide, autoantibody, SLE, dsDNA, Systemic rheumatic disease
Abstract: Since the first description of self-reactive antibodies in systemic autoimmune rheumatic diseases, many autoantigens have been identified as useful diagnostic biomarkers in clinical immunology. Among the autoantigens, double-stranded desoxoribonucleic acid (dsDNA), the Smith antigen (Sm), topoisomerase-I (topo-I), proliferating cell nuclear antigen (PCNA), and others were described as hallmark targets of systemic autoimmune diseases. The detection of the corresponding autoantibodies can be performed with a variety of immunoassays based on native antigens, recombinant proteins or synthetic peptides. As discussed in this review, synthetic peptides often represent highly accurate antigenic ligands for autoantibody assays that can be easily produced in high quality and quantity and with remarkable reproducibility. Furthermore, the use of peptides that focus on abrogation or neutralization of pathogenic autoantibodies provides a possible new therapeutic approach to the management of autoimmune disorders. There is an increasing number of interesting examples for the application of synthetic peptides in diagnostic approaches. Todays sophisticated epitope mapping methods will potentate the identification of further peptides that can be possibly used as specific targets in diagnostic and therapeutic approaches to improve the patients treatment. This may lead to a new scientific research area with high impact on the development of diagnostic and therapeutic products, to the area of peptide engineering and “theranostics”.
Export Options
About this article
Cite this article as:
Kessenbrock Kai, Raijmakers Reinout, Fritzler J. Marvin and Mahler Michael, Synthetic Peptides: The Future of Patient Management in Systemic Rheumatic Diseases?, Current Medicinal Chemistry 2007; 14 (26) . https://dx.doi.org/10.2174/092986707782360150
DOI https://dx.doi.org/10.2174/092986707782360150 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation
Current Drug Targets MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) The Role of Tec Family Kinases in Inflammatory Processes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of CTLA-4 Gene Polymorphisms in Autoimmune Disease Pathogenesis: A 2012 Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Current Immunology Reviews (Discontinued) Recent Patents on Immunoregulatory DNA Vaccines for Autoimmune Diseases and Allograft Rejection
Recent Patents on DNA & Gene Sequences Synthetic Peptides for the Immunodiagnosis of Human Diseases
Current Medicinal Chemistry Assessment of Endothelial Function by Positron Emission Tomography
Current Cardiology Reviews Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases
Current Pharmaceutical Design Role of the α7 Nicotinic Acetylcholine Receptor and RIC-3 in the Cholinergic Anti-inflammatory Pathway
Central Nervous System Agents in Medicinal Chemistry Effect of Recombinant Human Thymosin-α1, an Immuno-Modulating Peptide with 28 Amino Acids, on the Activity of Cytochrome P450s
Drug Metabolism Letters Celastrol and Terpenes as Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Molecular Field Analysis (MFA) and Other QSAR Techniques in Development of Phosphatase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Transplantation of Genetically Modified Haematopoietic Stem Cells to Induce Antigen-Specific Tolerance as a Cure for Autoimmune Diseases
Current Stem Cell Research & Therapy Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Current Molecular Medicine Multivalent Compounds for Antigen-Specific B Cell Tolerance and Treatment of Autoimmune Diseases
Current Medicinal Chemistry Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Interferon: Cellular Executioner or White Knight?
Current Medicinal Chemistry